Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: eico20 who wrote (1311)	6/17/2015 5:20:41 PM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

I did some limited research on the Androxal Phase 3 trial. Now there were several go-arounds with the FDA but it appears that the most recent head-to-head trial with Androgel involved an enrollment of only 120 and the previous Phase 3 for safety and efficacy involved 194 patients. I am more used to cancer trials involving two side-by-side trials each involving hundreds of patients for statistical power and costing mega bucks. So just maybe a Phase 3 Fispemifene trial won't cost the $60M - $100M that I was figuring. clinicaltrials.gov clinicaltrials.gov